BR112018008936A2 - métodos para a preparação de ácido obeticólico e derivados do mesmo - Google Patents

métodos para a preparação de ácido obeticólico e derivados do mesmo

Info

Publication number
BR112018008936A2
BR112018008936A2 BR112018008936A BR112018008936A BR112018008936A2 BR 112018008936 A2 BR112018008936 A2 BR 112018008936A2 BR 112018008936 A BR112018008936 A BR 112018008936A BR 112018008936 A BR112018008936 A BR 112018008936A BR 112018008936 A2 BR112018008936 A2 BR 112018008936A2
Authority
BR
Brazil
Prior art keywords
derivatives
preparation
methods
obeticolic acid
obeticolic
Prior art date
Application number
BR112018008936A
Other languages
English (en)
Inventor
M Galvin Gabriel
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of BR112018008936A2 publication Critical patent/BR112018008936A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a um método de preparação de um derivado de ácidos biliares, ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, compreendendo a alquilação direta na posição c-6 de klca.
BR112018008936A 2015-11-06 2016-10-28 métodos para a preparação de ácido obeticólico e derivados do mesmo BR112018008936A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562252077P 2015-11-06 2015-11-06
PCT/US2016/059440 WO2017079062A1 (en) 2015-11-06 2016-10-28 Methods for the preparation of obeticholic acid and derivatives thereof

Publications (1)

Publication Number Publication Date
BR112018008936A2 true BR112018008936A2 (pt) 2018-11-27

Family

ID=58662647

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008936A BR112018008936A2 (pt) 2015-11-06 2016-10-28 métodos para a preparação de ácido obeticólico e derivados do mesmo

Country Status (14)

Country Link
US (1) US10604545B2 (pt)
EP (1) EP3370728A4 (pt)
JP (1) JP6749406B2 (pt)
KR (1) KR20180067699A (pt)
CN (1) CN108348533A (pt)
AR (1) AR106587A1 (pt)
AU (1) AU2016350690C1 (pt)
BR (1) BR112018008936A2 (pt)
CA (1) CA3004275A1 (pt)
HK (1) HK1254055A1 (pt)
IL (1) IL258922A (pt)
MX (1) MX2018005520A (pt)
TW (1) TW201720839A (pt)
WO (1) WO2017079062A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110869381B (zh) 2017-07-26 2021-11-19 正大天晴药业集团股份有限公司 甾体类衍生物fxr激动剂的制备方法
CN107383139A (zh) * 2017-08-09 2017-11-24 杭州和泽医药科技有限公司 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
WO2021029656A1 (ko) * 2019-08-14 2021-02-18 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
EP4041722A4 (en) 2019-10-07 2023-12-13 Kallyope, Inc. GPR119 AGONISTS
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN115884978A (zh) 2020-08-21 2023-03-31 沙山一号有限责任公司 制备胆酸衍生物的方法及其原料
CA3235515A1 (en) 2021-11-02 2023-05-11 Sandhill One, Llc High purity non-animal derived tudca
WO2023081657A2 (en) 2021-11-02 2023-05-11 Sandhill One, Llc High purity non-animal derived udca
WO2023081166A1 (en) 2021-11-02 2023-05-11 Sandhill One, Llc Stereoselective steroidal reductions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303399T1 (de) * 2001-03-12 2005-09-15 Intercept Pharmaceuticals Inc Steroide als agonisten für fxr
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
KR102116955B1 (ko) 2012-02-07 2020-06-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 탄탈룸 코팅된 나노구조를 갖는 제조산물, 이를 제조 및 사용하는 방법
SG10201607230SA (en) 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid
KR102068381B1 (ko) * 2012-10-26 2020-01-20 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체의 제조 방법
CN104876995B (zh) * 2014-02-27 2016-09-07 人福医药集团股份公司 鹅去氧胆酸衍生物的制备方法
CN104558086B (zh) * 2014-12-25 2016-10-05 康美（北京）药物研究院有限公司 一种5β-3α,7α-二羟基-6α-乙基-胆烷酸的制备方法

Also Published As

Publication number Publication date
AU2016350690A1 (en) 2018-05-10
EP3370728A4 (en) 2019-07-10
AR106587A1 (es) 2018-01-31
EP3370728A1 (en) 2018-09-12
CN108348533A (zh) 2018-07-31
JP6749406B2 (ja) 2020-09-02
TW201720839A (zh) 2017-06-16
WO2017079062A1 (en) 2017-05-11
CA3004275A1 (en) 2017-05-11
US10604545B2 (en) 2020-03-31
HK1254055A1 (zh) 2019-07-12
US20190062367A1 (en) 2019-02-28
JP2018532800A (ja) 2018-11-08
AU2016350690C1 (en) 2020-04-23
MX2018005520A (es) 2018-08-01
IL258922A (en) 2018-06-28
KR20180067699A (ko) 2018-06-20
AU2016350690B2 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
BR112018008936A2 (pt) métodos para a preparação de ácido obeticólico e derivados do mesmo
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
BR112018015474A2 (pt) agonista de fxr derivado de esteroide
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
BR112018006892A2 (pt) moduladores do receptor farnesoide x
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112018001869A2 (pt) método para preparação de ácidos biliares e derivados dos mesmos
BR112017023161A2 (pt) composições de ácido obeticólico e métodos de uso
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
BR112015009395A2 (pt) processo para preparação de derivados do ácido biliar
BR112017002403A2 (pt) formas de cristais de inibidores de glutaminase
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112018011695A2 (pt) síntese diastereosseletiva de derivados fosfato e do pró-fármaco de gencitabina nuc-1031
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
BR112017006342A2 (pt) composto de sal de ácido benzenossulfônico, forma em estado sólido cristalino, composição farmacêutica, produto farmacêutico de combinação, método de tratamento de doenças ou condições, uso de um composto de sal de ácido benzenossulfônico, e, processo para preparação de um composto de sal de ácido benzenossulfônico.
BR112017009471A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
BR112017004140A2 (pt) sondas para imageamento de proteína de huntingtina
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
BR112018071441A2 (pt) métodos para a preparação de ácido obeticólico e derivados do mesmo
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112018012325A2 (pt) métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements